|
|
Article: Peregrine Pharmaceuticals Transitions Tarvacin Name to Official Generic Name Bavituximab.
- Article from:
- PR Newswire
- Article date:
- April 24, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TUSTIN, Calif., April 24 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for the treatment of hepatitis C virus infection and cancer, announced today it is transitioning from using the trade name Tarvacin for its first-in-class anti-phospholipid agent to bavituximab, the official generic name recently assigned by the United States Adopted Names Council. Bavituximab is in clinical trials for the treatment of hepatitis C viral infections and solid tumors.
The transition is being made partly because of regulatory concerns about potential confusion with marketed ...